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Introduction
The experience in the use of tumour necrosis factor
(TNF) antagonists in children below 4 years is limited,
although there are some trials in the literature which
support safety and efficacy under this age.
Objectives
To assess efficacy and safety of TNF-alpha antagonists
(anti-TNF) in a cohort of patients with Juvenile Idiopathic
Arthritis (JIA) who began treatment under 4 years-old.
Assess relapse rate after methotrexate and/or anti-TNF
withdrawal.
Methods
We made a retrospective charts review of our non-
systemic JIA patients treated with anti-TNF under
4 years of age between January 2006 and April 2013.
Demographics, epidemiologic, clinical, laboratory data
and rate of relapse after treatment withdrawal due to
clinical remission were collected. Efficacy and safety
endpoints included side-effects and time to achieve clin-
ical remission.
Results
We included 27 patients, 23 received etanercept and 4
adalimumab with a median age of 3.01 (range 0.88-3.97)
years at anti-TNF beginning and 1.94 (range 0.18-5.44)
and 2.39 (range 0.18-7.24) years of treatment and follow
up respectively. All patients had previously received
Disease Modifying Antirheumatic Drugs at optimal
dose. Nineteen patients reached clinical remission on
treatment in a median time of 9.1 (range 6.23-21.17)
months. Four of those relapsed during treatment.
Six developed mild side-effects (22.2%): 3 primary non
complicated varicella zoster virus infections, 1 pneumo-
nia, gastrointestinal and respiratory mild infections in a
patient with primary immunodeficiency and 1 case of
constipation. None serious side-effects were described.
Eleven patients who reached clinical remission relapsed
after treatment withdrawal. None achieved clinical
remission off treatment.
Conclusion
Most patients reached clinical remission on anti-TNF.
In our cohort of patients, etanercept and adalimumab
were safe, with mostly mild infections and no serious
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